CAS 70024-90-7 Recombinant HSA Low Endotoxin For Serum - Free Cell Culture

CAS 70024-90-7 Recombinant Serum Albumin HSA low endotoxin for serum-free cell culture

Quick detail

1. CAS No.: 70024-90-7
2. Other Names: Recombinant HSA, rHSA, OsrHSA
3. EINECS No.: 274-272-6
4. Place of Origin: Wuhan, China (Mainland)
5. Brand Name: Oryzogen
6. Catalog Number: HYC002M01
7. Purity: Greater than 99 % as determined by SDS-PAGE
8. Source: Rice Grain (Oryza Sativa)

Description

With years of effort, Healthgen Biotech has developed the State-of-the-Art platform called Oryz^HiExp, having high capacity to express no animal origin proteins and peptides in the rice endosperm cells.

Healthgen Biotech expressed and purified the human serum albumin (rHSA) from rice grain. The rHSA has high purity, more than 99%, and low endotoxin, less than 0.125EU/mg, and is animal origin free, which effectively avoid any potential risk of animal contaminants, bacteria, prions, virus and contagious protein disease. With the world's advanced facility and top production proceeding to extract and purify the rHSA, Healthgen Biotech can ensure the excellent consistency of rHSA from different batches.

Recombinant human serum albumin (rHSA) has good efficacy, such as rHSA has the same second and tertiary structure, physiological and biochemical properties with HSA from plasma. In addition, compared with HSA from plasma, rHSA has a lower immune source stimulation, and plays a better role in accelerating cell growth and metabolism, because rHSA is animal component free, which can avoid the prions or virus contaminants.

Healthgen Biotech quality control system has been certified by ISO 9001:2015 and ensure standardized process as well as qualified products.

Recombinant human serum albumin quality standard

Supplemental Description

Healthgen Biotech, always pay great attention to the original technological innovation and intellectual property protection, has the titles of “Hubei Province Molecular Pharmaceutical Engineering Research Center” and “Protein Purification Research Center”. The rice endosperm cell high expression technology platform and other core technology have applied and gained 13 domestic and international patents; and won the “2012 Hubei Provincial Science and technology invention Award”, “2013 National Science and Technology Invention Award and China Patent Excellence Award’. The project obtained the funding from the National Ministry of science and high technology “863 plan”, Major national science and technology plan “Major projects of new varieties of genetically modified organisms” and “Major projects for new drug discovery”, the National Development and Reform Commission “Pilot development of strategic emerging industries”, National Ministry of science and technology innovation fund and state and local plans for all kinds of talented people funding. In July 2015, Healthgen Biotech became a public company on the "China New OTCBB", a national share transfer system for SMEs and officially known as the National Equities Exchange and Quotations, which is the “first stock” of the plant-derived pharmaceutical in China and even the world.